Nanotechnology Now

Our NanoNews Digest Sponsors

Heifer International

Wikipedia Affiliate Button

Home > News > Pro-Pharmaceuticals Files Phase II Clinical Trial Protocol

July 25th, 2006

Pro-Pharmaceuticals Files Phase II Clinical Trial Protocol

Abstract:
Pro-Pharmaceuticals (Amex: PRW), a developer of novel nanotechnology carbohydrate compounds, today announced it has filed a clinical protocol with the U.S. Food & Drug Administration (FDA) for an open-label, up to 50 patient, multi-center Phase II study of DAVANAT(R) with Avastin(R).

Source:
businesswire

Bookmark:
Delicious Digg Newsvine Google Yahoo Reddit Magnoliacom Furl Facebook

Related News Press

Nanomedicine

Arrowhead Receives Regulatory Clearance to Begin Phase 1/2 Study of ARO-HBV for Treatment of Hepatitis B February 15th, 2018

Arrowhead Pharmaceuticals Receives Orphan Drug Designation for ARO-AAT February 15th, 2018

'Living bandages': NUST MISIS scientists develop biocompatible anti-burn nanofibers February 15th, 2018

Understanding brain functions using upconversion nanoparticles: Researchers can now send light deep into the brain to study neural activities February 14th, 2018

Announcements

Unconventional superconductor may be used to create quantum computers of the future: They have probably succeeded in creating a topological superconductor February 19th, 2018

Photonic chip guides single photons, even when there are bends in the road February 16th, 2018

Arrowhead Receives Regulatory Clearance to Begin Phase 1/2 Study of ARO-HBV for Treatment of Hepatitis B February 15th, 2018

Arrowhead Pharmaceuticals Receives Orphan Drug Designation for ARO-AAT February 15th, 2018

NanoNews-Digest
The latest news from around the world, FREE



  Premium Products
NanoNews-Custom
Only the news you want to read!
 Learn More
NanoTech-Transfer
University Technology Transfer & Patents
 Learn More
NanoStrategies
Full-service, expert consulting
 Learn More











ASP
Nanotechnology Now Featured Books




NNN

The Hunger Project